Further immunohistochemical and molecular analysis of these tumours, particularly the identification of the characteristic translocation (t(2;5)(p23;q35)) and the successful cloning of the breakpoints by Steve Morris and Tom Look in 1994, revealing fusion of the nucleolar phosphoprotein gene nucleophosmin 1 (npm1) with that of a newly described gene, anaplastic lymphoma kinase (alk), led to the establishment of the entity now known as ALK-positive Anaplastic Large Cell Lymphoma (ALCL) [3,4,5,6]. The gene discussed is NPM1; the disease is neoplasm.